Antiretrovirals may increase risk for ESLD, HCC in patients with HIV
The cumulative use of several antiretrovirals, including d-drugs Zerit, Videx, Viread and Agenerase, were independently associated with increased rates of end-stage liver disease and hepatocellular carcinoma among adults with HIV.
Researchers, including Lene Ryom, MD, PhD, of the University of Copenhagen, department of infectious diseases, Denmark, conducted a retrospective cohort study and followed patients with HIV who were receiving antiretroviral drugs such as Zerit (stavudine, Bristol-Myers Squibb), Videx (didanosine, Bristol-Myers Squibb) Viread (tenofovir, Gilead Sciences) and Agenerase (amprenavir, Glaxo Wellcome Inc.) until evidence of end-stage liver disease (ESLD) or HCC, death, 6 months after last visit or January 2014. Any associations between ESLD/HCC and cumulative use of individual antiretrovirals were measured using Poisson regression analysis adjusting for potential confounders, according to the research.
Over a median follow-up of 8.4 years, 319 cases of ESLD/HCC occurred, indicating an incidence rate of 1.01 per 1,000 person-years (95% CI, 0.9-1.12). This incidence rate led to a 62.6% mortality rate at 1 year.
“In a large heterogeneous cohort of HIV-positive individuals, the incidence of ESLD/HCC … was relatively low and driven primarily by co-infection with viral hepatitis,” Ryom told Healio.com/Hepatology.
After adjusting for multiple confounders, the cumulative exposure to use of stavudine (relative rate (RR) = 1.46; 95% CI, 1.2-1.77), didanosine (RR = 1.32; 95% CI, 1.07-1.63), tenofovir (RR = 1.46; 95% CI, 1.11-1.93) or amprenavir (RR = 1.47; 95% CI, 1.01-2.15) was associated with increased rates of ESLD/HCC. These associations with increased ESLD/HCC rates declined 6 years after cessation, according to the research.
“There was limited evidence for reversibility of ESLD/HCC risk upon cessation of d-drugs (didanosine and stavudine), and intensified monitoring of liver function and avoidance of hepatotoxic compounds should hence be considered amongst all with longer-term current or prior d-drug exposure,” Ryom said.
The researchers concluded: “The use of d-drugs should furthermore be avoided, where there are alternatives available and focus should be put on those with longer-term d-drugs exposure who remain at increased ESLD/HCC risk. The unexpected, and viral hepatitis independent, [tenofovir] association calls for further investigations.” – by Melinda Stevens
Disclosure: Healio.com/Hepatology was unable to confirm relevant financial disclosures at the time of publication.